{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:33:40Z","timestamp":1782182020510,"version":"3.54.5"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bja.2017.11.082","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T17:56:45Z","timestamp":1513706205000},"page":"645-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants"],"prefix":"10.1016","volume":"120","author":[{"given":"J.W.","family":"Eikelboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kozek-Langenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Exadaktylos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Batorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Boda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Christory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gornik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"K\u0117k\u0161tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Komadina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Koval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mitic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Novikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pazvanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ratobilska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"S\u00fctt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Winder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zateyshchikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2017.11.082_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jth.12969","article-title":"Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH","volume":"13","author":"Barnes","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","article-title":"Overview of the new oral anticoagulants: opportunities and challenges","volume":"35","author":"Yeh","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bja.2017.11.082_bib3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.bja.2017.11.082_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11239-013-0885-0","article-title":"Reversal of novel oral anticoagulants in patients with major bleeding","volume":"35","author":"Siegal","year":"2013","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.bja.2017.11.082_bib5","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2013a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/jth.12308","article-title":"Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels","volume":"11","author":"Hawes","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.bja.2017.11.082_bib8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5858\/arpa.2014-0170-OA","article-title":"Use of thromboelastography (TEG) for detection of new oral anticoagulants","volume":"139","author":"Dias","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.bja.2017.11.082_bib9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijcard.2014.07.084","article-title":"Monitoring of dabigatran anticoagulation and its reversal in\u00a0vitro by thrombelastography","volume":"176","author":"Solbeck","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.bja.2017.11.082_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijcard.2016.01.148","article-title":"Thrombelastography detects dabigatran at therapeutic concentrations in\u00a0vitro to the same extent as gold-standard tests","volume":"208","author":"Solbeck","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.bja.2017.11.082_bib11","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc13717","article-title":"Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation\/liver trauma experimental model","volume":"18","author":"Grottke","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.bja.2017.11.082_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.thromres.2017.03.018","article-title":"Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment","volume":"153","author":"Taune","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.bja.2017.11.082_bib13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1515\/cclm-2013-0936","article-title":"Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests","volume":"52","author":"Eller","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.bja.2017.11.082_bib14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cll.2014.06.008","article-title":"Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays","volume":"34","author":"van Ryn","year":"2014","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.bja.2017.11.082_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.bja.2017.11.082_bib16","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/jth.12702","article-title":"Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography\u2013tandem mass spectrometry (UPLC-MS\/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants","volume":"12","author":"Schmitz","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib18","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/jth.12720","article-title":"Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents","volume":"12","author":"Dale","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1160\/TH13-10-0871","article-title":"Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels","volume":"111","author":"Francart","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1309\/AJCPQ2NJD3PXFTUG","article-title":"Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay","volume":"143","author":"Morishima","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bja.2017.11.082_bib21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.thromres.2014.08.006","article-title":"Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry","volume":"134","author":"Adelmann","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.bja.2017.11.082_bib22","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00101-012-2091-4","article-title":"Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM","volume":"61","author":"Casutt","year":"2012","journal-title":"Anaesthesist"},{"key":"10.1016\/j.bja.2017.11.082_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.cll.2014.06.009","article-title":"Pharmacology and laboratory testing of the oral Xa inhibitors","volume":"34","author":"Samama","year":"2014","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.bja.2017.11.082_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.bja.2017.11.082_bib25","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.drudis.2014.05.013","article-title":"Reversal of target-specific oral anticoagulants","volume":"19","author":"Siegal","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bja.2017.11.082_bib26","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/blood-2013-09-529784","article-title":"How I treat target-specific oral anticoagulant-associated bleeding","volume":"123","author":"Siegal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bja.2017.11.082_bib27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00508-013-0430-3","article-title":"Management of dabigatran-induced bleeding: expert statement","volume":"125","author":"Fries","year":"2013","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.bja.2017.11.082_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11239-013-0923-y","article-title":"Reversal of target-specific oral anticoagulants","volume":"36","author":"Kaatz","year":"2013","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.bja.2017.11.082_bib29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/ALN.0000000000000608","article-title":"Prothrombin complex concentrates in trauma and perioperative bleeding","volume":"122","author":"Grottke","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2017.11.082_bib30","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1017\/S0265021508004675","article-title":"Prothrombin complex concentrates: a brief review","volume":"25","author":"Samama","year":"2008","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.bja.2017.11.082_bib31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ajh.23254","article-title":"Prothrombin complex concentrates in emergency bleeding disorders","volume":"87","author":"Rodgers","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bja.2017.11.082_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1160\/TH11-01-0052","article-title":"Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis","volume":"106","author":"Dentali","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib33","first-page":"189","article-title":"Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?","volume":"111","author":"Dickneite","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13054-016-1275-8","article-title":"Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation","volume":"20","author":"Grottke","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.bja.2017.11.082_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12245-015-0059-2","article-title":"Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran","volume":"8","author":"McGovern","year":"2015","journal-title":"Int J Emerg Med"},{"key":"10.1016\/j.bja.2017.11.082_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11239-014-1112-3","article-title":"Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report","volume":"39","author":"Masotti","year":"2015","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.bja.2017.11.082_bib37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jcpt.12339","article-title":"Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban","volume":"41","author":"Durie","year":"2016","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.bja.2017.11.082_bib38","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.wneu.2015.08.042","article-title":"Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors","volume":"84","author":"Grandhi","year":"2015","journal-title":"World Neurosurg"},{"key":"10.1016\/j.bja.2017.11.082_bib39","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"Hoffman","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.2002.00532.x","article-title":"Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events","volume":"8","author":"Ehrlich","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.bja.2017.11.082_bib41","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/CCM.0b013e31827caaa3","article-title":"Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity","volume":"41","author":"Dager","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bja.2017.11.082_bib42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bjh.12620","article-title":"Activated prothrombin complex concentrate for dabigatran-associated bleeding","volume":"164","author":"Schulman","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bja.2017.11.082_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/14779072.2015.987126","article-title":"Monitoring and reversal strategies for new oral anticoagulants","volume":"13","author":"Vanden Daelen","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.bja.2017.11.082_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/asheducation-2013.1.44","article-title":"The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders","volume":"2013","author":"Ragni","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"Suppl 1","key":"10.1016\/j.bja.2017.11.082_bib45","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0268-960X(15)30006-0","article-title":"Safety update on the use of recombinant activated factor VII in approved indications","volume":"29","author":"Neufeld","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.bja.2017.11.082_bib46","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials","volume":"363","author":"Levi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bja.2017.11.082_bib47","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.bja.2017.11.082_bib48","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1538-7836.2012.04863.x","article-title":"Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate","volume":"10","author":"Lambourne","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","article-title":"Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model","volume":"116","author":"Godier","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2017.11.082_bib50","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1016\/j.ijcard.2013.07.152","article-title":"Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis","volume":"168","author":"Martin","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.bja.2017.11.082_bib51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/ALN.0000000000000540","article-title":"Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate","volume":"122","author":"Hoffman","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2017.11.082_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001886.pub3","article-title":"Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion","author":"Henry","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bja.2017.11.082_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bja.2017.11.082_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13054-016-1265-x","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition","volume":"20","author":"Rossaint","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.bja.2017.11.082_bib55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40256-013-0055-y","article-title":"Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects","volume":"14","author":"Wang","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.bja.2017.11.082_bib56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s13181-012-0276-5","article-title":"Positive outcome after intentional overdose of dabigatran","volume":"9","author":"Woo","year":"2013","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.bja.2017.11.082_bib57","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1160\/TH12-08-0573","article-title":"Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease","volume":"109","author":"Khadzhynov","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib58","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jth.13117","article-title":"Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib59","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1160\/TH14-06-0547","article-title":"Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis","volume":"113","author":"Parasrampuria","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3810\/pgm.2014.11.2829","article-title":"Reversal agents in development for the new oral anticoagulants","volume":"126","author":"Costin","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.bja.2017.11.082_bib61","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A\u00a0specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bja.2017.11.082_bib62","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A\u00a0randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib63","first-page":"269","article-title":"Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers","volume":"26","author":"Schmohl","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bja.2017.11.082_bib64","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bja.2017.11.082_bib65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40262-016-0417-0","article-title":"Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover Phase Ib study","volume":"56","author":"Glund","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bja.2017.11.082_bib66","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.jacc.2016.01.043","article-title":"Restarting dabigatran etexilate 24 h after reversal with idarucizumab and redosing idarucizumab in healthy volunteers","volume":"67","author":"Glund","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.bja.2017.11.082_bib67","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2013full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bja.2017.11.082_bib68","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab: the antidote for reversal of dabigatran","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.bja.2017.11.082_bib69","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A\u00a0specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bja.2017.11.082_bib70","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet\u00a0alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bja.2017.11.082_bib71","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet\u00a0alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bja.2017.11.082_bib72","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bja.2017.11.082_bib73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/emermed-2012-201976","article-title":"The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran","volume":"31","author":"Alikhan","year":"2014","journal-title":"Emerg Med J"},{"key":"10.1016\/j.bja.2017.11.082_bib74","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00508-014-0581-x","article-title":"Dabigatran: patient management in specific clinical settings","volume":"126","author":"Kyrle","year":"2014","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.bja.2017.11.082_bib75","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.acvd.2013.04.009","article-title":"Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)\u2013March 2013","volume":"106","author":"Pernod","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.bja.2017.11.082_bib76","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/imj.12448","article-title":"New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural\/bleeding management","volume":"44","author":"Tran","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.bja.2017.11.082_bib77","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.113.005754","volume":"129","author":"Sherwood","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.bja.2017.11.082_bib78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2016.01.004","article-title":"Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial","volume":"139","author":"Douketis","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.bja.2017.11.082_bib79","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/eurheartj\/eht557","article-title":"Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry","volume":"35","author":"Beyer-Westendorf","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.bja.2017.11.082_bib80","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/EJA.0b013e32833f6f6f","article-title":"Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology","volume":"27","author":"Gogarten","year":"2010","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.bja.2017.11.082_bib81","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/EJA.0000000000000630","article-title":"Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016","volume":"34","author":"Kozek-Langenecker","year":"2017","journal-title":"Eur J Anaesthesiol"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091217540775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091217540775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:12:31Z","timestamp":1762103551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091217540775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0007091217540775"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2017.11.082","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2017.11.082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd on behalf of British Journal of Anaesthesia.","name":"copyright","label":"Copyright"}]}}